Free tool
FAERS Monitor: Vancocin Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050606 or its brand name (Vancocin Hydrochloride, Vancomycin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
8,212
Serious
7,409
90% of reports
Hospitalization
3,669
Death reported
1,633
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective874
- acute kidney injury582
- off label use519
- pyrexia482
- rash345
- drug reaction with eosinophilia and systemic symptoms317
- pneumonia310
- sepsis310
- drug hypersensitivity305
- diarrhoea296
- condition aggravated283
- hypotension258
- renal failure254
- dyspnoea240
- pruritus226
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 51 |
| 2006 | 92 |
| 2007 | 150 |
| 2008 | 271 |
| 2009 | 101 |
| 2010 | 92 |
| 2011 | 108 |
| 2012 | 167 |
| 2013 | 236 |
| 2014 | 217 |
| 2015 | 320 |
| 2016 | 230 |
| 2017 | 244 |
| 2018 | 361 |
| 2019 | 468 |
| 2020 | 524 |
| 2021 | 682 |
| 2022 | 964 |
| 2023 | 959 |
| 2024 | 818 |
| 2025 | 699 |
| 2026 | 396 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,947 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug reaction with eosinophilia and systemic symptomsSignal | 317 | 31.9 | 28.6 | 9,363 |
| acute kidney injurySignal | 582 | 9.8 | 9.0 | 4,591 |
| sepsisSignal | 310 | 7.1 | 6.4 | 1,633 |
| renal failureSignal | 254 | 4.9 | 4.3 | 790 |
| drug hypersensitivitySignal | 305 | 4.0 | 3.6 | 700 |
| pyrexiaSignal | 482 | 3.6 | 3.3 | 903 |
| hypotensionSignal | 258 | 3.3 | 2.9 | 414 |
| pneumoniaSignal | 310 | 2.5 | 2.2 | 269 |
| condition aggravatedSignal | 283 | 2.4 | 2.1 | 229 |
| rashSignal | 345 | 2.0 | 1.8 | 182 |
| drug ineffective | 874 | 1.7 | 1.6 | 267 |
| off label use | 519 | 1.5 | 1.4 | 95 |
| pruritus | 226 | 1.5 | 1.3 | 39 |
| diarrhoea | 296 | 1.2 | 1.1 | 8 |
| dyspnoea | 240 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.